---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-005155"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:37:48.203448+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics prices $90M public offering of 60M shares at $1.50 per share

## Summary
- Offering of 60M shares of common stock at $1.50/share; gross proceeds ~$90M before expenses.
- Underwriters granted 30-day option to purchase up to 9M additional shares at same price.
- Closing expected on or about Jan 27, 2023; proceeds for general corporate purposes.
- Directors and executive officers subject to lock-up agreements until April 25, 2023.
- Credit Suisse and William Blair act as active book-running managers; Oppenheimer as passive.

## SEC filing metadata
- accession: 0001213900-23-005155
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/0001213900-23-005155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/ea172170-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-005155
- JSON: https://secwatch.observer/filing/0001213900-23-005155.json
- Plain text: https://secwatch.observer/filing/0001213900-23-005155.txt

## Key facts
- Material Agreements
  Jasper Therapeutics, Inc. entered into Underwriting Agreement with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. valued at approximately $90 million (effective 2023-01-25).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc.
  - Value: approximately $90 million
  - Effective: 2023-01-25
  source text: On January 25, 2023, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc., as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 60,000,000 shares of the Company’s voting common stock, $0.0001 par value per share (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/0001213900-23-005155-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.